Insulin efsitora alfa

Insulin efsitora alfa
Clinical data
Other names	LY3209590; LY-3209590
Identifiers
CAS Number	2131038-11-2 ;
UNII	OZ465SMQ28 ;
KEGG	D13028 ;

Last updated June 28, 2025

Insulin efsitora alfa (LY3209590) is a novel insulin analog developed by Eli Lilly for the treatment of diabetes. Its glycemic control and safety were found similar to insulin degludec in a phase II trial.^[1]^[2]^[3]

Research

A systematic review and metanalysis of insulin efsitora alfa, published in 2024, found that it may be useful in the management of type 1 and type 2 diabetes.^[4]

References

↑ Heise, Tim; Chien, Jenny; Beals, John M.; Benson, Charles; Klein, Oliver; Moyers, Julie S.; Haupt, Axel; Pratt, Edward John (2023). "Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes". Diabetes, Obesity and Metabolism. 25 (4): 1080–1090. doi: 10.1111/dom.14956 . PMID 36541037. S2CID 255034380.
↑ Moyers, Julie S.; Hansen, Ryan J.; Day, Jonathan W.; Dickinson, Craig D.; Zhang, Chen; Ruan, Xiaoping; Ding, Liyun; Brown, Robin M.; Baker, Hana E.; Beals, John M. (2022). "Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein". Journal of Pharmacology and Experimental Therapeutics. 382 (3): 346–355. doi: 10.1124/jpet.122.001105 . PMID 35840338.
↑ Kazda, Christof M.; Bue-Valleskey, Juliana M.; Chien, Jenny; Zhang, Qianyi; Chigutsa, Emmanuel; Landschulz, William; Wullenweber, Paula; Haupt, Axel; Dahl, Dominik (2023). "Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes". Diabetes Care. 46 (5): 1052–1059. doi:10.2337/dc22-2395. PMC 10154655 . PMID 36920867.
↑ Dutta D, Nagendra L, Kumar M, Kamrul-Hasan AB, Bhattacharya S (December 2024). "Optimal use of once-weekly basal insulin efsitora alfa in type 1 and type 2 diabetes: A systematic review and meta-analysis". Endocrine Practice. doi:10.1016/j.eprac.2024.12.013. PMID 39710291.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Heise, Tim; Chien, Jenny; Beals, John M.; Benson, Charles; Klein, Oliver; Moyers, Julie S.; Haupt, Axel; Pratt, Edward John (2023). "Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes". Diabetes, Obesity and Metabolism. 25 (4): 1080–1090. doi: 10.1111/dom.14956 . PMID 36541037. S2CID 255034380.

[2] Moyers, Julie S.; Hansen, Ryan J.; Day, Jonathan W.; Dickinson, Craig D.; Zhang, Chen; Ruan, Xiaoping; Ding, Liyun; Brown, Robin M.; Baker, Hana E.; Beals, John M. (2022). "Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein". Journal of Pharmacology and Experimental Therapeutics. 382 (3): 346–355. doi: 10.1124/jpet.122.001105 . PMID 35840338.

[3] Kazda, Christof M.; Bue-Valleskey, Juliana M.; Chien, Jenny; Zhang, Qianyi; Chigutsa, Emmanuel; Landschulz, William; Wullenweber, Paula; Haupt, Axel; Dahl, Dominik (2023). "Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes". Diabetes Care. 46 (5): 1052–1059. doi:10.2337/dc22-2395. PMC 10154655 . PMID 36920867.

[4] Dutta D, Nagendra L, Kumar M, Kamrul-Hasan AB, Bhattacharya S (December 2024). "Optimal use of once-weekly basal insulin efsitora alfa in type 1 and type 2 diabetes: A systematic review and meta-analysis". Endocrine Practice. doi:10.1016/j.eprac.2024.12.013. PMID 39710291.

[1]

[2]

[3]

[4]